One fund owns the big drugmakers that pay dividends. The other owns the broader biotech field, where stocks swing more. Here is which fits long-term investors.
VanEck's concentrated 26-stock portfolio delivered stronger five-year returns and lower volatility, while State Street's 62-holding fund offers broader diversification and lower fees.
IHE has outperformed recently by concentrating in U.S. drugmakers. PPH offers global reach and a higher dividend for investors willing to trade some of that momentum for income.
VanEck offers lower costs and higher dividends with a concentrated pharma focus, while Simplify provides broader healthcare exposure and donates profits to breast cancer research.
VanEck offers lower costs and double the dividend yield, while Invesco delivered stronger 1-year returns with more balanced holdings.
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.
VanEck's concentrated 26-stock portfolio has outpaced Fidelity's broader 334-holding fund over five years, but at a steeper cost and higher volatility.
This is the newest page. Registered accounts read further back.